Recent findings indicate that the STING pathway may be deficient in certain types of tumor cells [55], which is consistent with sufficiency of RNA-dependent RLR responses to radio/chemotherapy in tumor cells and/or cells of mesenchymal origin, described in this report. The gene discussed is STING1; the disease is neoplasm.